Remus Pharmaceuticals Q3 Results
- BSE: -
- NSE: REMUS
- ISIN: INE0O5T01011
- Sector: Biotechnology & Drugs
BSE
This stock is not traded on BSE
NSE
671.00
-29.00 (-4.14%)
-29.00 (-4.14%)Volume3.40 K
Updated: Fri 13 Feb, 2026 | 15:20:22
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Quarter ended Dec 22
Note: Comparison is on QoQ basis
Quarterly - Remus Pharmaceuticals Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 22 | Sep 23 | QoQ Comp |
|---|---|---|---|
| Total Operating Expense | 24.78 | 20.19 | N/A |
| Depreciation/ Amortization | 0.33 | 0.42 | N/A |
| Operating Income | 7.61 | 8.85 | N/A |
| Net Income | 6.44 | 5.65 | N/A |
| Other Operating Expenses Total | 0.00 | 2.88 | N/A |
| Net Income Before Taxes | 8.69 | 10.41 | N/A |
| Total Revenue | 32.39 | 29.04 | N/A |
| Selling/ General/ Admin Expenses Total | 9.12 | 3.29 | N/A |
| Diluted Normalized EPS | 5.47 | 5.19 | N/A |